



## Recent Advances in the Pharmacology of Peripheral Neuropathy

Guest Editors:

**Dr. Claire Demiot**

UR 20218-NeurIT, Faculties of  
Medicine and Pharmacy,  
University of Limoges, 87025  
Limoges, France

**Dr. Amandine Rovini**

UR 20218-NeurIT, Faculties of  
Medicine and Pharmacy,  
University of Limoges, 87025  
Limoges, France

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Peripheral neuropathies encompass a broad array of conditions that involve damage to the peripheral nervous system which affect millions of people worldwide and remain difficult to treat. Peripheral neuropathy can result from inherited causes as well as traumatic injuries, infections, metabolic problems including diabetes, and exposure to chemotherapy. Current options are mainly symptomatic and supportive with medical treatment including physical therapy and if needed, pain medication. Similarly, patients with inherited peripheral neuropathies, are provided life-long supportive care, but again there are currently no treatments or cures. Therefore, there is a significant need to discover therapies that offer both longitudinal and sustained management of neuropathic symptoms. Furthermore, since different types of neuropathies may respond differently to a given drug, there is a need for studies where predictive factors for response are identified.

This Pharmaceuticals Special Issue invites both reviews and original articles regarding basic, preclinical, and clinical studies relevant as potential therapeutic options for patients with CIPN and inherited peripheral neuropathies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)